STAT· @statnews · X·· 22 天前精选AI 评分78
AI 导读
默沙东与中国科伦博泰开发的一种靶向化疗药物在晚期子宫内膜癌患者中将死亡风险降低三分之一。相关研究结果在ESMO 2026上公布,STAT News报道了该数据。
推荐理由
默沙东与科伦博泰的ADC在晚期子宫内膜癌中把死亡风险降低三分之一,读者可据此了解该疗法的疗效量级。
正文
A type of targeted chemotherapy developed by Merck and China’s Kelun-Biotech cut by one-third the risk of death in patients with advanced endometrial cancer. https://www.statnews.com/2026/10/26/merck-kelun-sac-tmt-endometrial-cancer-study-esmo-2026/
来源:STAT · x.com